DaimlerChrysler merger: The involvement of the boards
This case can be used to analyze the level of involvement of the boards during the merger negotiations between Daimler-Benz AG and Chrysler Corporation. This transatlantic “merger of equals” provides an excellent opportunity for evaluating the corporate governance approaches across the Atlantic. It also gives participants a real life example for discussing the converging roles of boards. The case starts with a brief history of both Daimler-Benz AG and the Chrysler Corporation, then goes on to explain the intricacies of corporate governance in this merger. The German model of corporate governance (two-tier boards, co-determination) is compared to the American system (inside and outside directors). At the end, participants are confronted with a list of issues facing the combined board. The case provides the basis for a discussion on how to overcome some different approaches in corporate governance and how to manage mega-mergers (e.g. organization of the post-merger-integration phase, remuneration, closeness to shareholders).
1995-1999
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case B looks at Sandoz once it has become independent. The hard work of figuring out the best way to spin off is done, a new strategy created, and so...
The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical coverage it had had in its many years as part of Novartis? Or should it focus on fewer ...
This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor's (CEO, Sandoz) ruminations as he builds the company strategy in preparation for the board's approval of Sandoz as a st...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-2670 ©2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-2669 ©2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 4 September 2025
Research Information & Knowledge Hub for additional information on IMD publications